Clinical trial · Interventional
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
NCT02928861CI-TRIAL-00024214unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Large B-Cell, Diffuse | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-FDG PET/CT-based prognostic model
- description
- The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
- interventionNames
- Device: 18F-FDG PET/CT
Primary outcomes (1)
- measure
- 2 year progression-free survival
- timeFrame
- up to 2 years after initial diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. newly diagnosed DLBCL; 2. treated using an anthracycline-containing regimen with or without rituximab; 3. minimal follow-up at 6 months after the completion of first-line treatment; 4. complete medical history and clinicopathological data Exclusion Criteria: 1. secondary malignant disease; 2. serious infection or inflammation (e.g., HIV); 3. primary central nervous system lymphoma; 4. hepatic or renal dysfunction.
References
Publications (2)
- DERIVEDYuan T, Chen X, Zhang Y, Wei M, Zhu H, Yang Z, Wang X. A novel prognostic index for diffuse large B-cell lymphoma combined baseline metabolic tumour volume with clinical and pathological risk factors. Nucl Med Commun. 2023 Jul 1;44(7):622-630. doi: 10.1097/MNM.0000000000001701. Epub 2023 Apr 28. PMID 37114393
- DERIVEDYuan T, Zhang Y, Chen X, Wei M, Zhu H, Song Y, Yang Z, Zhu J, Wang X. Risk Assessment in Diffuse Large B-Cell Lymphoma by Combining Baseline Metabolic Tumor Volume and Peking Criteria When Evaluating Series 18F-Fluorodeoxyglucose Positron Emission Tomography Scans. Front Oncol. 2022 Apr 21;12:876581. doi: 10.3389/fonc.2022.876581. eCollection 2022. PMID 35530320